uniQure N.V. (QURE) News
Track canonical SquawkNews coverage tagged to QURE, uniQure N.V.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 20 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
RBC Reiterates QURE Outperform
RBC reiterates QURE Outperform rating
EQUITY | Jul 30, 2026, 11:06 AM UTC
H
QURE Upgraded to Outperform
QURE upgraded to Outperform
EQUITY | Jul 30, 2026, 11:05 AM UTC
H
HSBC, Jefferies, Mizuho Upgrade Stocks
Multiple stocks upgraded by analysts
EQUITY | Jul 30, 2026, 10:41 AM UTC
L
QURE +11% on Q2 Revenue Beat
QURE beats Q2 revenue estimates
EARNINGS | Jul 29, 2026, 01:34 PM UTC
H
Some earnings movers to upside from today, premarket: AVTR +13% LFUS +11% GEHC +9% GNRC +9% HAYW +8% OPCH +6% APH +6% QURE +6% E +6%
Some earnings movers to upside from today, premarket: AVTR +13% LFUS +11% GEHC +9% GNRC +9% HAYW +8% OPCH +6% APH +6% QURE +6% E +6%
EARNINGS | Jul 29, 2026, 12:58 PM UTC
L
QURE rises after Q2 revenue beat
QURE beats Q2 revenue estimates
EARNINGS | Jul 29, 2026, 11:33 AM UTC
L
QURE - uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
QURE - uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
EARNINGS | Jul 29, 2026, 11:05 AM UTC
L
Uniqure Insider Sold Shares Worth $952,051, According to a Recent SEC Filing
() -- Matthew C Kapusta, Director, CEO, and Managing Director, on July 02, 2026, sold 21,082 shares in Uniqure (QURE) for $952,051. Following the Form 4 filing with the SEC, Kapusta has control over a total of 519,227 or
REGULATION | Jul 07, 2026, 08:54 PM UTC
L
Uniqure Insider Sold Shares Worth $983,030, According to a Recent SEC Filing
() -- Jack Kaye, Director, on June 30, 2026, sold 21,167 shares in Uniqure (QURE) for $983,030. Following the Form 4 filing with the SEC, Kaye has control over a total of 25,996 ordinary shares of the company, with 25,99
REGULATION | Jul 02, 2026, 09:04 PM UTC
M
CAPR Falls 13%
Capricor Therapeutics stock is trading lower after the FDA plans to convene an advisory committee meeting to discuss the company's Biologics License Application for Deramiocel
EQUITY | Jun 26, 2026, 06:06 PM UTC
M
QURE Upsizes Public Offering
uniQure announces closing of upsized public offering and full exercise by underwriters of option to purchase additional shares
EQUITY | Jun 25, 2026, 08:10 PM UTC
M
QURE: Mizuho Raises Target
Mizuho analyst raises uniQure price target to $68 and maintains Outperform rating
EQUITY | Jun 25, 2026, 04:17 PM UTC
M
QURE Prices $225M Offering
uniQure announces pricing of upsized $225 million public offering
EQUITY | Jun 24, 2026, 09:13 AM UTC
M
QURE Prices $225M Offering
uniQure prices upsized $225M public offering of 4,945,055 ordinary shares at $45.50 per share
EQUITY | Jun 24, 2026, 05:51 AM UTC
L
CDNL: Proposes Public Offering
CDNL proposes public offering of common stock
EQUITY | Jun 23, 2026, 09:24 AM UTC
M
CDNL: Proposes Public Offering
CDNL proposes public offering of common stock, among other equity offerings from various companies
EQUITY | Jun 22, 2026, 09:10 PM UTC
M
QURE: Announces $150M Offering
uniQure announces a $150 million offering.
EQUITY | Jun 22, 2026, 08:06 PM UTC
M
QURE Launches $150M Offering
uniQure announces a proposed public offering of $150 million
EQUITY | Jun 22, 2026, 08:01 PM UTC
H
RGNX: FDA Reconsiders Gene Therapy
Regenxbio aligns with FDA on next steps for potential accelerated approval of Navsunli gene therapy
EQUITY | Jun 22, 2026, 01:23 PM UTC
M
QURE: Reports Prelim Data
uniQure announces preliminary data on the first cohort in the Phase I/IIa clinical trial of AMT-260 in refractory mesial temporal lobe epilepsy
EQUITY | Jun 19, 2026, 11:27 AM UTC